Cesamet Related Published Studies
Well-designed clinical trials related to Cesamet (Nabilone)
Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. [2010.11]
A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. [2010.05]
The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. [2010.02.01]
A pilot study using nabilone for symptomatic treatment in Huntington's disease. [2009.11.15]
Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. [2008.04]
Nabilone for the treatment of pain in fibromyalgia. [2008.02]
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. [2008.01.26]
Nabilone for the Treatment of Pain in Fibromyalgia. [2007.10.30]
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. [2006.10]
Effects of nabilone, a synthetic cannabinoid, on postoperative pain. [2006.08]
[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial] [2006.06]
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. [2005.06]
Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. [1994.08]
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. [1988.04]
A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. [1987.09]
Well-designed clinical trials possibly related to Cesamet (Nabilone)
Examining the roles of cannabinoids in pain and other therapeutic indications: a review. [2010.01]
Examining the roles of cannabinoids in pain and other therapeutic indications: a
review. [2010]
Are cannabinoids a new treatment option for pain in patients with fibromyalgia? [2008.07]
Are cannabinoids a new treatment option for pain in patients with fibromyalgia? [2008.06.03]
Cannabinoids in medicine: A review of their therapeutic potential. [2006.04.21]
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. [2002.01]
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. [2001.12.11]
Other research related to Cesamet (Nabilone)
An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. [2011.07]
Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta9-tetrahydrocannabinol. [2010.09]
The abuse potential of the synthetic cannabinoid nabilone. [2010.03]
A randomized, double-blinded, crossover pilot study assessing the effect of
nabilone on spasticity in persons with spinal cord injury. [2010]
The effects of nabilone on sleep in fibromyalgia: results of a randomized
controlled trial. [2010]
Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. [2009.06.12]
Nabilone for the treatment of paraneoplastic night sweats: a report of four cases. [2008.07]
Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. [2008.03]
Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. [2008.01]
Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. [2006.01]
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. [2002.01]
Other possibly related research studies
The emerging role of cannabinoid neuromodulators in symptom management. [2007.01]
Guidelines for the use of cannabinoid compounds in chronic pain. [2005.09]
Cannabinoids and multiple sclerosis. [2002.08]
Cannabis and cannabinoids: pharmacology and rationale for clinical use. [1999.10]
Pharmacokinetic optimisation of antiemetic therapy. [1992.08]
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. [2006.10]
Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. [2006.02]
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. [2005.05]
[Cannabinoids and the immune system. Of men, mice and cells] [2004.06]
Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. [2003]
Medical marijuana initiatives : are they justified? How successful are they likely to be? [2003]
Therapeutic potential of cannabinoids in CNS disease. [2003]
Cannabinoids for gastrointestinal diseases: potential therapeutic applications. [2003.01]
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. [2001.07.07]
Cannabinoids in clinical practice. [2000.12]
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. [2001.02]
Laboratory detection of cannabinoids. [1987.09]
Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. [2007.05]
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. [2007.06]
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. [2007.09]
Reassessment of the role of cannabinoids in the management of pain. [2007.10]
Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. [2008.07.03]
Cannabinoids in the management of difficult to treat pain. [2008.02]
Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. [2008.09]
[What sense in cannabinoid use as regulated by Italian DM 18/04/07? Pharmacological and legal considerations] [2008.06]
Chemotherapy-induced nausea and vomiting. [2008.03]
Fungal biotransformation of cannabinoids: potential for new effective drugs. [2009.03]
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. [2009.02]
The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). [2009.01]
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. [2009.02]
Cannabinoids, endocannabinoids, and related analogs in inflammation. [2009.03]
[Cannabinoids in medicine] [2008]
A treatment algorithm for neuropathic pain: an update. [2009.12]
Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. [2010]
Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. [2010.01]
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. [2009.10]
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. [2011.11]
Using cannabinoids in pain and palliative care. [2010.10]
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of
randomized trials. [2011]
|